ZBIO vs KYMR

For growth investors, Zenas BioPharma, Inc.

(ZBIO) is the stronger pick with 100. 0% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Analysts rate Zenas BioPharma, Inc. (ZBIO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +64. 1%, compared to -1. 2% for Zenas BioPharma, Inc. (ZBIO). Over 10 years, the gap is even starker: KYMR returned +149. 4% versus ZBIO's -1. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.

(KYMR) is the lower-risk stock at 0. 90β versus Zenas BioPharma, Inc. 's 1. 39β — meaning ZBIO is approximately 55% more volatile than KYMR relative to the S&P 500. On balance sheet safety, Kymera Therapeutics, Inc. (KYMR) carries a lower debt/equity ratio of 5% versus 33% for Zenas BioPharma, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zenas BioPharma, Inc.

(ZBIO) is pulling ahead at 100. 0% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Kymera Therapeutics, Inc. grew EPS -23. 8% year-over-year, compared to -124. 5% for Zenas BioPharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Kymera Therapeutics, Inc.

(KYMR) is the more profitable company, earning -794. 4% net margin versus -37. 8% for Zenas BioPharma, Inc. — meaning it keeps -794. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYMR leads at -891. 3% versus -21. 1% for ZBIO. At the gross margin level — before operating expenses — ZBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), +149. 4% 10Y return). Both have compounded well over 10 years (KYMR: +149. 4%, ZBIO: -1. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZBIO is a small-cap high-growth stock; KYMR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.